Business Context and Reporting Period
This Form 8-K is a current report filed by Supernus Pharmaceuticals, Inc. on August 20, 2014, covering events occurring on August 14, 2014 and August 19, 2014. The company is a Delaware corporation focused on pharmaceutical development.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current event disclosure and does not contain financial statements or performance metrics.
Material Changes
No material financial changes versus a prior comparable period are reported in this document. The filing focuses on regulatory milestones and corporate communications.
Guidance, Outlook, and Management Commentary
- Regulatory Milestone: On August 14, 2014, the U.S. Food and Drug Administration (FDA) granted fast track designation for the company's candidate drug, SPN-810. This designation is for the treatment of impulsive aggression in attention deficit hyperactivity disorder (ADHD).
- Investor Relations: On August 19, 2014, management announced plans to host investor meetings during the FBR Healthcare Conference on September 3, 2014.
Important Facts for Investor Verification
- Verify the specific criteria and implications of the FDA fast track designation for SPN-810 regarding the treatment of impulsive aggression in ADHD.
- Confirm the schedule and outcomes of the investor meetings held at the FBR Healthcare Conference on September 3, 2014.
- Review the full text of the press releases attached as Exhibit 99.1 and Exhibit 99.2 for additional details not summarized in the 8-K body.